Delay in colonoscopy following positive screening test associated with increased risk of colorectal

April 25, 2017

Among patients with a positive fecal immunochemical test result, compared with follow-up colonoscopy at 8 to 30 days, follow-up after 10 months was associated with a higher risk of colorectal cancer and more advanced-stage disease at the time of diagnosis, according to a study published by JAMA.

Colorectal cancer is the second leading cause of cancer death in the United States. The fecal immunochemical test (FIT) is commonly used for colorectal cancer screening and positive test results need to be followed by a complete colon examination, typically with colonoscopy; however, recommendations for how quickly to complete follow-up differ and lack a strong evidence base. Douglas A. Corley, M.D., Ph.D., of Kaiser Permanente Northern California, Oakland, and colleagues conducted a study that included patients with a positive FIT result who had a follow-up colonoscopy.

Of the 70,124 patients with positive FIT results (median age, 61 years; men, 53 percent), there were 2,191 cases of any colorectal cancer and 601 cases of advanced-stage disease diagnosed. The researchers found that there was no significant increase in risk of overall colorectal cancer or advanced colorectal cancer associated with colonoscopy follow-up within 10 months compared with 8 to 30 days.

There was a higher risk of stage II colorectal cancer at 7 to 9 months; of any colorectal cancer, advanced-stage disease, and stage II and IV colorectal cancer at 10 to 12 months; and of advanced adenomas, any colorectal cancer, advanced-stage disease, and stages II-IV colorectal cancer at more than 12 months.

"Further research is needed to assess whether this relationship is causal," the authors write.
-end-
For more details and to read the full study, please visit the For The Media website.

(doi:10.1001/jama.2017.3634)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

To place an electronic embedded link to this study in your story This link will be live at the embargo time: http://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2017.3634

The JAMA Network Journals

Related Colorectal Cancer Articles from Brightsurf:

Colorectal cancer treatment: the winning combinations
Chemotherapy has distressing side effects for patients and increases the risk of developing resistance to the treatment.

A new model to predict survival in colorectal cancer
This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy.

Roadmap to reducing colorectal cancer deaths
The American Gastroenterological Association has outlined a strategy to increase the number of people screened via tests that are more convenient, accurate and less expensive and tailored to people's individual cancer risks.

Study provides new insight on colorectal cancer growth
A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase to facilitate colorectal cancer growth.

Researchers ID target for colorectal cancer immunotherapy
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.

Colorectal cancer partner-in-crime identified
A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.

Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.

A novel pathway to target colorectal cancer
Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes.

Colorectal cancer rates in Canada
The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.

Cancer drugs promote stem cell properties of colorectal cancer
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.

Read More: Colorectal Cancer News and Colorectal Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.